Precision Peptide Company granted 600,000 restricted share units to a director and 1,100,000 stock options to directors, officers, and consultants, with options exercisable at $0.50 per share for three years. The company also settled $125,000 of debt owed to its CEO by issuing 300,000 common shares at a deemed price of $0.42 each. These moves are part of the company's incentive plan and debt management strategy, with shares issued subject to regulatory hold periods. This reflects ongoing efforts to align management incentives and manage liabilities as the company advances its peptide wellness products in North America.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
NEWMEDIA.COM highlights that top ecommerce web design agencies prioritize conversion and scale over just appearance, addressing the nearly 70% cart abandonment rate largely caused by fixable user experience issues like slow pages and complicated chec...
The global waterborne epoxy resins market, valued at $4.98 billion in 2024, is projected to grow at a CAGR of 6.03% to $8.51 billion by 2034. This growth is fueled by strict international regulations targeting volatile organic compound emissions and ...
Valeo has disclosed the total number of voting rights and shares composing its share capital as of June 30, 2026. The company reported a capital of €245,607,624 with 245,607,624 shares, theoretical voting rights totaling 276,898,916, and exercisable ...
